Regulated Expansion

Authorities treat the case as scientifically important but insist on conventional clinical evidence before broad use. Radical Numerics moves toward a small, supervised Phase 1/2 study, while hospitals and payers remain cautious about single-patient results.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.